Top Evidence-Based Interventions to Lower Biological Age

Epigenetic aging clocks estimate biological age based on DNA molecular tagging patterns, and interventions like semaglutide and ketamine reduce these estimates in humans.

(The principal investigator behind the review on interventions that influence biological age, Dr. David Sinclair | The Society of the Four Arts)

As reviewed in this article, epigenetic aging clocks have estimated the effects of pharmaceutical interventions, lifestyle habits, supplements, and clinical interventions on biological age.

Aging &amp; Longevity

Participants: Prefrail older adults
Dosage: 50 mg/day of losartan for at least 8 weeks

Losartan, a common blood pressure medication, increases the survival rate of mice and improves the metabolic outlook of pre-frail older adults. 

Principal Investigator of the study, Dr. Peter M. Abadir (image: jhu.edu).

Cellular reprogramming, an innovative age-reversal technology, stimulates the regeneration of heart cells after a heart attack in mice. 

Cardiovascular

Peter Fedichev’s Physics-Based Approach to Aging: A New Longevity Framework

Peter Fedichev describes aging as a three-variable system of stress (from physical, psychological, or molecular stressors), noise (small random biological fluctuations), and damage (cumulative wear-and-tear).

Peter Fedichev has proposed a physics-based framework for aging, encompassing stress, noise (small random biological fluctuations), and damage (cumulative wear-and-tear).

Participants: Sedentary older adults 
Dosage: 6 mg/week of rapamycin

In older adults, the FDA-approved drug rapamycin, associated with prolonging lifespan, blunts improvements in physical performance.

Search Result: longevity drug

Top Evidence-Based Interventions to Lower Biological Age

New Johns Hopkins Study: FDA-Approved Losartan May Extend Lifespan

New Age-Reversing Tech Helps Heart Regenerate, Scientists Find

Peter Fedichev’s Physics-Based Approach to Aging: A New Longevity Framework

Rapamycin and Exercise: New Study Finds Potential Performance Decline